{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:42:02Z","timestamp":1792172522615,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10147-024-02532-0","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T15:01:11Z","timestamp":1714316471000},"page":"994-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study"],"prefix":"10.1007","volume":"29","author":[{"given":"Sho","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ssuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Hokamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichiro","family":"Saze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Kunisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-8217","authenticated-orcid":false,"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,28]]},"reference":[{"key":"2532_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2532_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-015-1716-9","volume":"14","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Kim S, Kim M et al (2015) Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study. BMC Cancer 14(15):693","journal-title":"BMC Cancer"},{"key":"2532_CR3","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","volume":"33","author":"H Bleiberg","year":"1997","unstructured":"Bleiberg H, Conroy T, Paillot B et al (1997) Randomised Phase II Study of Cisplatin and 5Fluorouracil (5FU) Versus Cisplatin Alone in Advanced Squamous Cell Oesophageal Cancer. Europ J Cancer 33:1216\u20131220","journal-title":"Europ J Cancer"},{"issue":"398","key":"2532_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"28","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 28(398):759\u2013771","journal-title":"Lancet"},{"key":"2532_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449\u2013462","journal-title":"N Engl J Med"},{"key":"2532_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Ashley A-RE et al (2023) Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol 41:1470\u20131491","journal-title":"J Clin Oncol"},{"key":"2532_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","volume":"25","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, Nakagawa K (2020) Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 25:818\u2013830","journal-title":"Int J Clin Oncol"},{"key":"2532_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10147-019-01588-7","volume":"25","author":"K Chamoto","year":"2020","unstructured":"Chamoto K, Hatae R, Honjo T (2020) Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol 25:790\u2013800","journal-title":"Int J Clin Oncol"},{"key":"2532_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"issue":"23","key":"2532_CR10","first-page":"02405","volume":"S0140\u20136736","author":"A Oaknin","year":"2023","unstructured":"Oaknin A, Gladieff L, Mart\u00ednez-Garc\u00eda J et al (2023) Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet S0140\u20136736(23):02405\u201302414","journal-title":"Lancet"},{"key":"2532_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000527114","volume":"101","author":"S Satake","year":"2023","unstructured":"Satake S, Arigami T, Matsushita D et al (2023) Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer. Oncology 101:12\u201321","journal-title":"Oncology"},{"key":"2532_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s10147-022-02200-1","volume":"27","author":"Y Aoki","year":"2022","unstructured":"Aoki Y, Kawazoe A, Kubota Y et al (2022) Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. Int J Clin Oncol 27:1413\u20131420","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"2532_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) RECIST version 1.1 JCOG ver1.0. Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"2532_CR14","unstructured":"Common Terminology Criteria for Adverse Events v5.0: Institute NC. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed Sep 2023"},{"key":"2532_CR15","doi-asserted-by":"publisher","first-page":"1219929","DOI":"10.3389\/fimmu.2023.1219929","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ma W, Qiu Z et al (2023) Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front Immunol 14:1219929","journal-title":"Front Immunol"},{"key":"2532_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10388-022-00920-x","volume":"19","author":"T Kojima","year":"2022","unstructured":"Kojima T, Hara H, Tsuji A et al (2022) First-line pembrolizumab + chemotherapy in Japanese patients with advanced\/metastatic esophageal cancer from KEYNOTE-590. Esophagus 19:683\u2013692","journal-title":"Esophagus"},{"key":"2532_CR17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ags3.12489","volume":"5","author":"S Sato","year":"2021","unstructured":"Sato S, Oshima Y, Matsumoto Y et al (2021) The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study. Ann Gastroenterol Surg 5:794\u2013803","journal-title":"Ann Gastroenterol Surg"},{"issue":"12","key":"2532_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834564","volume":"3","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhang Z, Li Y et al (2022) Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Front Oncol 3(12):834564","journal-title":"Front Oncol"},{"issue":"9","key":"2532_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CJI.0000000000000438","volume":"45","author":"L Chang","year":"2022","unstructured":"Chang L, Cheng Q, Ma Y et al (2022) Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor. J Immunother 45(9):415\u2013422","journal-title":"J Immunother"},{"key":"2532_CR20","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ccell.2023.06.006","volume":"41","author":"TM Carroll","year":"2023","unstructured":"Carroll TM, Chadwick JA, Owen RP et al (2023) Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell 41:1222\u20131241","journal-title":"Cancer Cell"},{"key":"2532_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M et al (2022) International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6:227\u2013240","journal-title":"Ann Gastroenterol Surg"},{"key":"2532_CR22","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1245\/s10434-019-07790-1","volume":"26","author":"S Sato","year":"2019","unstructured":"Sato S, Kunisaki C, Tanaka Y et al (2019) Curative-Intent Surgery for Stage IV Advanced Gastric Cancer: Who Can Undergo Surgery and What Are the Prognostic Factors for Long-Term Survival? Ann Surg Oncol 26:4452\u20134463","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2532_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ags3.12623","volume":"7","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Tsushima T, Kato K et al (2022) Defining conversion therapy for esophageal squamous cell carcinoma. Ann Gastroenterol Surg 7(1):7\u20139","journal-title":"Ann Gastroenterol Surg"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02532-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T06:06:36Z","timestamp":1719209196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02532-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02532-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3855013\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,28]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors S.S, T.K, K.K, H.Y, H.S, Y.M, Y.I, Y.S, S.H, and H.S received lecture fee from Ono pharmaceutical co., ltd. Authors S.S and S.H received lecture fee from Bristol Myers Squibb co. Authors S.S, K.K, H.Y, and H.S received lecture fee from Taiho pharmaceutical co. ltd. Authors S.S, K.K, H.Y, H.S, Y.M, S.H, and H.S received lecture fee from MSD co. ltd. Authors S.S and K.K received lecture fee from DAIICHI SANKYO co. ltd. Authors K.K and H.Y received lecture fee from Chugai pharmaceutical co. Authors Y.I, H.Y, and K.K received lecture fee from Takeda pharmaceutical co., ltd. Author H.Y received lecture fee from Yakult Honsha co., ltd. Authors I.E and H.S received research grant from Ono pharmaceutical co., ltd. Authors H.Y, C.K, and H.S received research grant from Taiho pharmaceutical co. ltd. Authors H.Y, C.K, I.E, and Y.I received research grant from Chugai pharmaceutical co. Authors Y.S and C.K received research grant from Yakult Honsha co., ltd. Author Y.I received research grant from Takeda pharmaceutical co. ltd and Shionogi pharmaceutical co. ltd. Author I.E received research grant from Asahi Kasei Pharma corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}